Global Pharmacogenomics Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Pharmacogenomics Market was valued at $10.2 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 10.7% CAGR, to an estimated market size of $16.9 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The pharmacogenomics market involves the study and application of how an individual's genetic makeup influences their response to drugs, encompassing the development and sale of testing kits, reagents, software, and services. The scope includes technologies like Next-Generation Sequencing (NGS) and PCR used to optimize drug selection and dosage, improve therapeutic efficacy, and minimize adverse drug reactions (ADRs) across clinical and research settings.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Pharmacogenomics Market in the period 2025-30:
- The structural shift toward Precision Medicine is moving healthcare away from 'one-size-fits-all' models to customized therapeutic strategies.
- Integration of Artificial Intelligence (AI) and machine learning is accelerating the speed and accuracy of genetic variant identification and drug response prediction.
- Sustained reductions in Next-Generation Sequencing (NGS) costs are broadening clinical access and enabling high-throughput testing in hospital systems.
- Rising pressure to reduce preventable Adverse Drug Reactions (ADRs), a major cause of hospitalization, is driving institutional investment in pre-prescription screening.
- The incorporation of pharmacogenomic data into Electronic Health Records (EHRs) is facilitating real-time clinical decision support at the point of care.
- Increasing Regulatory Support and mandates for pharmacogenomic labeling on therapeutic products are forcing wider adoption by pharmaceutical developers.
- The expansion of Companion Diagnostics is becoming a standard requirement for the approval and reimbursement of targeted therapies.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Oncology
- Neurology & Psychiatry
- Cardiology
- Pain Management
- Other Applications